drugset
drugset / Trial / NCT05305183

A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis

NCT05305183 ↗

Phase 3 Unknown 330 enrolled Shandong New Time Pharmaceutical Co., LTD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In the randomized, active-controlled, double-blinded, multicenter study, the efficacy and safety of monthly oral minodronate were examined and compared to that of weekly oral alendronate.

Timeline

Start
2022-05-31
Primary completion
2023-05-31
Completion
2024-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 70 mg Oral
Subject Minodronic acid Small molecule 50 mg Oral
Background Calcium carbonate Other / unclassified — —
Background Cholecalciferol Other / unclassified — —

Indications

osteoporosis